Remote Monitoring of CGM Data in Pediatric Patients With Newly Diagnosed Type 1 Diabetes (T1D)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
To determine if increased targeted contact between patients and the care team can improve diabetes outcomes in the 1st year after diagnosis. We will be using the GluVue platform to remotely view continuous glucose monitor (CGM) data. Based on alerts from GluVue, care team members will proactively reach out to patients and their families for more frequent dose adjustments. We will assess if remote monitoring facilitates contact between the care team and patients and improves glycemic control.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 21 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All individuals within one month of T1D diagnosis seen at the Stanford Children's Diabetes Clinic
Individuals who plan to receive follow up care at the Stanford Children's Diabetes Clinic
Individuals who agree to CGM data integration into the electronic medical record (EMR) for remote monitoring
Age: birth to < 21 years of age
Diabetes diagnosis other than T1D
Diagnosis of diabetes > 1 month prior to initial visit
Individuals with the intention of obtaining diabetes care at another clinic
Individuals who do not consent to CGM use, CGM data integration, or remote monitoring